US Patent 8,460,704 Scope, Claims, and U.S. Patent Landscape for Once-Daily Nevirapine 400 mg Tablets for HIV-1 Treatment
US Patent 8,460,704 is a narrow, formulation-and-dosing-frequency method claim tied to a specific once-daily tablet composition and compression parameter. Its protective scope is driven by: (i) a method of treating HIV-1 infection, (ii) once-daily administration, (iii) a tablet having exact component masses, and (iv) tablets compressed using a specified force range (10–25 kN). Any U.S. infringement analysis will therefore turn on whether an accused product and use match all elements in combination.
What does US Patent 8,460,704 claim and what must be proven for infringement?
Core claim type. The claim is a “method for treating” HIV-1 infection that is limited to administration of a once-daily tablet with a defined composition and a defined compression force. In practice, infringement of Claim 1 requires proof of both:
- the clinical dosing regimen (once daily), and
- the tablet’s physical/manufacturing and compositional characteristics.
Claim 1 elements (as provided):
- “A method for treating HIV-1 infection”
- “which comprises once daily administration”
- “to a human infected by HIV-1”
- “a tablet pharmaceutical dosage form”
- “wherein each tablet comprises”
- (a) 400 mg anhydrous nevirapine
- (b) 270 mg Hypromellose 2208
- (c) 400 mg lactose monohydrate
- (d) 10 mg magnesium stearate
- “wherein each tablet is compressed by a force of 10–25 kN”
Immediate scope implication. The claim is not a broad “nevirapine once-daily” method claim. It is a “nevirapine once-daily tablet with exact formulation and compression-force” method claim. Changing any single element is a non-trivial design-around.
Is the compression-force limitation a practical barrier?
Because the claim specifies “compressed by a force of 10–25 kN,” infringement is tied to manufacturing conditions. In U.S. patent litigation, that can be proved through:
- manufacturing records, batch manufacturing documentation, or validated process parameters; and
- expert testimony correlating reported tooling and press settings to compression force.
Even where the same formulation is used, a different compression force range can avoid literal infringement. A generic or reformulation maker typically treats these process constraints as potential “off-ramps.”
What counts as “once daily” in claim scope?
The claim requires “once daily administration.” A regimen that is twice daily, twice-weekly, or includes breaks does not meet the literal “once daily” limitation. Scheduling variations that still amount to once per 24-hour cycle generally increase risk of overlap, but exact clinical practice and labeling matter for method claims.
What is the composition scope: how exact are the tablet component masses?
The claim uses hard mass values for each component per tablet:
- 400 mg anhydrous nevirapine
- 270 mg Hypromellose 2208
- 400 mg lactose monohydrate
- 10 mg magnesium stearate
Equality matters. Mass values typically require matching the claimed amounts. If an accused tablet has different mg quantities for any listed ingredient, it can fall outside literal scope.
Potential partial overlap. If a tablet has the same overall excipient identity but different mg amounts, the key issue becomes whether the patent uses any interpretive flexibility (for example, ranges, tolerances, or “about” language). Based solely on the claim wording as provided, the masses appear fixed, not ranged. That tends to make the claim easier to design around by reformulation.
Hypromellose 2208 is a sub-specification
“Hypromellose 2208” is a specific grade. Substituting a different hypromellose grade (even if chemically similar) is a direct design-around if the claim is construed strictly to the named grade.
Lactose monohydrate is also specified
Replacing lactose monohydrate with lactose anhydrous, another sugar, or a different filler can avoid literal infringement.
How is the tablet dosage form tied to HIV-1 treatment in the claim?
The claim is not a standalone pharmaceutical product claim. It is a method-of-use claim that requires administration “to a human infected by HIV-1.”
This framing matters for infringement theory:
- A product manufacturer generally does not “administer.” The practical infringement defendant is often the entity that induces infringement through labeling, instructions, and product promotion that results in once-daily use in HIV-1 treatment settings.
- In Paragraph IV style disputes, the arguments frequently focus on whether the generic will be labeled or used in a way that meets the method claim.
What patents likely surround US 8,460,704 in scope: formulation, dosing frequency, and manufacturing parameters?
Without the full specification text and the rest of the patent family, a complete, evidence-backed landscape cannot be enumerated from the claim alone. Still, the landscape around this type of claim is typically structured into three clusters:
- Nevirapine formulation patents
- tablet compositions using specific excipients and ratios
- dissolution and bioavailability improvements
- anhydrous vs. hydrated forms
- Dosing regimen / sustained-release / once-daily patents
- once-daily or extended-release nevirapine dosing methods
- method-of-use claims tied to PK/PD rationales
- Manufacturing-process patents
- compression force, tooling, or tableting parameters
- granulation steps, blending, milling, drying, or compaction settings
- process validation and scale-up claims
US 8,460,704 is most aligned with the intersection of (1) formulation specificity and (3) tableting process specificity, with the clinical use anchored by once-daily administration.
Claim-driven overlap analysis: where competitors are most likely to infringe
If a competitor makes a tablet with the same anhydrous nevirapine amount and the same excipient masses and uses a compression force in the 10–25 kN window, then both the product and the “once-daily administration” method limitation could be met through intended use.
Where competitors are most likely to design around
The highest-probability off-ramps are:
- change excipient masses or swap grade (Hypromellose 2208)
- replace lactose monohydrate
- change magnesium stearate amount
- change compression force outside 10–25 kN
- change the intended dosing regimen so it is not once daily per labeling or instructions
When does the patent lose exclusivity in the U.S.?
A U.S. expiration date depends on:
- the filing date (and thus term under 35 U.S.C. 154),
- any patent term adjustment (PTA),
- any terminal disclaimers,
- and any patent term extension (PTE), typically uncommon for this type of patent unless tied to pediatric or other statutory mechanisms.
The claim text provided does not include filing date, priority, or prosecution history. Therefore, an accurate U.S. exclusivity timeline cannot be produced from the claim alone.
What is the Orange Book status of this patent and how does it affect generic entry risk?
Orange Book listing status, listed NDCs, and “use code” or “dosage form” codes determine the practical “FDA trigger” for Paragraph IV challenges to method-of-use patents.
The claim text provided does not identify:
- the reference listed drug (RLD),
- the associated NDCs,
- or whether the patent is listed as a composition, method-of-use, or both.
Without that, a correct Orange Book mapping cannot be generated.
What Paragraph IV challenges are likely for US 8,460,704 given the claim elements?
Method claims that require exact tablet composition and manufacturing force are often challenged on one or more of these grounds:
- Noninfringement: a proposed generic tablet does not match the recited excipient masses or compression force.
- Invalidity: obviousness or lack of novelty over prior nevirapine tableting/formulation disclosures.
- Indefiniteness or lack of written description/enablement if the spec does not support the narrow formulation and process details.
Given the claim’s narrowness, noninfringement is usually the main litigation axis for design-around products. Invalidity still matters, especially if older disclosures already contain near-identical once-daily nevirapine tablets with tableting parameters.
How strong is the patent estate for this specific dosing regimen and composition?
Claim 1 is strong in the sense that it is tightly limited. That reduces the range of non-optimized products that could infringe. The tradeoff is enforceability against only closely matched products.
Key strength factors embedded in the claim:
- exact ingredient masses,
- specified excipient grade,
- and specified compression-force range.
Key fragility factors:
- if prior art already teaches the same composition and tableting parameters for nevirapine tablets, validity risk increases;
- if the specification lacks detail supporting compression-force limitation, written description/enabling disclosure attacks become relevant;
- if the accused product changes even one parameter, infringement weakens.
What would an accused generic need to do to avoid infringing US 8,460,704 Claim 1?
From the claim elements provided, a safe design-around typically requires at least one of the following:
- Not once daily administration (change regimen so it is not “once daily”).
- Tablet not having 400 mg anhydrous nevirapine per tablet.
- Tablet with different excipient masses, e.g., Hypromellose 2208 not 270 mg.
- Tablet uses Hypromellose grade not “2208.”
- Tablet uses excipient profile not exactly as claimed (lactose monohydrate not 400 mg; magnesium stearate not 10 mg).
- Tablet compression force outside 10–25 kN during tableting (or use a process that demonstrably never hits the recited force band).
How does US 8,460,704 compare with typical nevirapine patent strategies (composition vs. method-of-use vs. sustained release)?
Compared with broader nevirapine “once-daily” strategy patents, US 8,460,704 is:
- more formulation-specific than dosing-regimen-only claims; and
- more process-specific than purely composition claims.
Compared with sustained-release nevirapine patents, it is not claiming a release mechanism in the claim text provided. Its distinctiveness is the tablet component package and compression force band, not a release profile limitation.
Key Takeaways
- US 8,460,704 Claim 1 is a narrow method-of-use claim that requires once-daily administration of a tablet with exact per-tablet ingredient masses and a defined compression-force range of 10–25 kN.
- Infringement requires matching all claim elements together: HIV-1 treatment context, once-daily dosing, exact tablet composition, and tableting compression-force.
- The most practical design-arounds are altering excipient masses/grades, replacing lactose monohydrate, changing magnesium stearate amount, or using compression forces outside 10–25 kN.
FAQs
- Can a generic avoid infringement if it uses the same nevirapine and excipients but different tablet compression settings?
- Does once-daily administration depend on FDA labeling, or can real-world practice trigger infringement for a method-of-use claim?
- If a product matches the formulation but is administered twice daily, does it avoid Claim 1 of US 8,460,704?
- How do courts treat claims that specify exact ingredient amounts and specific excipient grades (e.g., Hypromellose 2208)?
- What are the most common invalidity theories for narrowly drafted formulation and manufacturing-parameter claims?
References
- United States Patent 8,460,704 (Claim 1 as provided by the user).
